AR059886A1 - Derivados de amidas como inhibidores de renina - Google Patents

Derivados de amidas como inhibidores de renina

Info

Publication number
AR059886A1
AR059886A1 ARP070100947A ARP070100947A AR059886A1 AR 059886 A1 AR059886 A1 AR 059886A1 AR P070100947 A ARP070100947 A AR P070100947A AR P070100947 A ARP070100947 A AR P070100947A AR 059886 A1 AR059886 A1 AR 059886A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
alkoxy
ch2ch2
ch2ch2ch2
Prior art date
Application number
ARP070100947A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR059886A1 publication Critical patent/AR059886A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto de la Formula (1) donde X representa CH, N, o N+-O-; W representa un fenilo para-sustituido, un piridilo para-sustituido, o un tiazolilo; V representa -CH2CH2CH2-, -CH2CH2-A-, -CH2-A-CH2-, -A-CH2CH2-, -CH2CH2CH2CH2-, - A-CH2CH2CH2-, -CH2-A-CH2CH2-, -CH2CH2-A-CH2-, -CH2CH2CH2-A-, -A-CH2CH2-B-, CH2CH2CH2CH2CH2-, -A-CH2CH2CH2CH2-, -CH2-A-CH2CH2CH2-, -CH2CH2-A-CH2CH2, -CH2CH2CH2-A-CH2-, -CH2CH2CH2CH2-A-, -A-CH2CH2CH2-B-, CH2-A-CH2CH2-B-, -A-CH2CH2-B-CH2-, -A-CH2CH2CH2- B-CH2-, -CH2-A-CH2CH2CH2-B-, o -O-CH2-Q-, donde Q está ligado al grupo U de Formula 1, o V representa un pirrodinilo de la Formula (2); U representa arilo no sustituido; arilo mono-, di-, tri- o tetra-sustituido, donde los sustituyentes se seleccionan independientemente del grupo formado por alquilo-C1-7, -CF3, halogeno, e hidroxi-alquilo-C1-7; o heteroarilo de cinco miembros con dos heteroátomos seleccionados independientemente entre nitrogeno, oxígeno y azufre, donde dicho radical heteroarilo está opcionalmente mono-, di- o tri-sustituido, donde los sustituyentes se seleccionan independientemente del grupo formado por alquilo-C1-7, alcoxi-C1-7, -CF3, -OCF3, y halogeno; Q representa un heteroarilo de cinco miembros con dos o tres heteroátomos seleccionados independientemente entre O y N; L representa -CH2-CH2-, -CH2-CH(R6)-CH2-, -CH2-N(R7)-CH2-, -CH2-O-CH2-, o -CH2-S-CH2-; A y B representan independientemente uno del otro -O- o -S-; R1 representa alquilo-C1-7 o cicloalquilo; R2 representa halogeno o alquilo-C1-7; R3 representa hidrogeno, halogeno, alquilo-C1-7, alcoxi-C1-7, o -CF3; R4 representa hidrogeno; alquilC1-7-O-(CH2)0-4-CH2-; CF3-O-(CH2)0-4-CH2-; R'2N-(CH2)0-4-CH2-, donde R' se selecciona independientemente del grupo formado por hidrogeno, alquilo-C1-7 (opcionalmente sustituido con uno a tres fluor), ciclopropilo (opcionalmente sustituido con uno a tres fluor), ciclopropil-alquilo-C1-7 (opcionalmente sustituido con uno a tres fluor), y -C(=O)-R'' donde R'' es alquiloC1-4, alcoxiC1-4, -CF3, -CH2-CF3, o ciclopropilo; o R13-C(=O)-(O)0-1-(CH2)0-4, donde R13 es alquiloC1-4, alcoxiC1-4, o ciclopropilo; donde R' y R'' preferiblemente no representan hidrogeno al mismo tiempo; R5 representa hidroxi, alcoxi-C1-7, hidroxi-alquilo-C1-7, dihidroxi-alquilo-C1-7, dihidroxi-alquilo-C1-7, alcoxi-C1-7-alquilo-C1-7, alcoxi-C1-7-alcoxi-C1-7-alquilo-C1-7, hidroxi-alcoxi-C1-7-alquilo-C1-7, carbamoil-alcoxi-C1-7, o alquilC1-7-carboniloxi; R6 representa -H, -CH2OR9, -CH2NR8R9, -CH2NR8COR9, -CH2NR8SO2R9, -CO2R9, -CH2OCONR8R9, -CONR8R9, -CH2NR8CONR8'R9, -CH2SO2NR8R9, -CH2SR9, -CH2SOR9, o -CH2SO2R9; R7 representa -R9, -COR9, -COOR11, -CONR8R9, -C(NR8)NR8'R9, -CSNR8R9, CSNR8R9, -SO2R9, o - SO2NR8R9; o R7 representa un radical de la Formulas (3) donde T representa -CH2-, -NH- o -O-, r es un numero entero entre 1 y 6 y s es un numero entero entre 1 y 4; R8 y R8' representan independientemente hidrogeno, alquilo-C1-7, alquenilo.C2-7, cicloalquilo, o cicloalquil-alquilo-C1-7, donde alquilo-C1-7, cicloalquilo, y cicloalquil-alquilo-C1-7 pueden estar sustituidos con uno, dos, o tres halogenos; R9 representa hidrogeno, alquilo-C1-7, cicloalquilo, o cicloalquil-alquilo-C1-7, donde alquilo-C1-7, cicloalquilo, y cicloalquil-alquilo-C1-7 pueden estar mono-, di- o tri-sustituidos, donde los sustituyentes se seleccionan independientemente del grupo formado por halogeno, hidroxi, -OCOR12, -COOR12, alcoxi-C1-7, ciano, SO2R12, - CONR12R12', morfolin-4-il-co-, ((4-alquilC1-7)piperazin-1-il)-CO-, -NHC(NH)NH2, -NR10R10' y alquilo-C1-7, con la condicion de que un átomo de carbono esté ligado a lo sumo a un heteroátomo en caso de que este átomo de carbono esté sp3-hibridizado; R10 y R10' representan independientemente hidrogeno, alquilo-C1-7, cicloalquilo, cicloalquil-alquilo-C1-7, hidroxi, alquilo-C1-7, -COOR8, o -CONH2; R11 representa halogeno, alquilo-C1-7, alcoxi-C1-7, -CF3, o hidrogeno; R12 y R12' representan independientemente hidrogeno, alquilo-C1-7, alquenilo-C2-7, cicloalquilo, o cicloalquil-alquilo-C1-7, donde alquilo-C1-7, cicloalquilo, y cicloalquil-alquilo-C1-7 pueden estar sustituidos con uno, dos, o tres halogenos; n representa el numero entero 0 o 1; y m representa el numero entero 0 o 1, con la condicion de que m representa el numero entero 1 si n representa el numero entero 1; y a sales de los mismos. También comprende aspectos relacionados que incluyen procesos para la preparacion de los compuestos, composiciones farmacéuticas que contienen uno o más de dichos compuestos y especialmente su uso como inhibidores de renina.
ARP070100947A 2006-03-08 2007-03-07 Derivados de amidas como inhibidores de renina AR059886A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2006050724 2006-03-08

Publications (1)

Publication Number Publication Date
AR059886A1 true AR059886A1 (es) 2008-05-07

Family

ID=38475245

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100947A AR059886A1 (es) 2006-03-08 2007-03-07 Derivados de amidas como inhibidores de renina

Country Status (18)

Country Link
US (1) US20090062342A1 (es)
EP (1) EP1994026A2 (es)
JP (1) JP2009529033A (es)
KR (1) KR20090008211A (es)
CN (1) CN101395149A (es)
AR (1) AR059886A1 (es)
AU (1) AU2007224368A1 (es)
BR (1) BRPI0708567A2 (es)
CA (1) CA2642436A1 (es)
CL (1) CL2007000595A1 (es)
IL (1) IL193885A0 (es)
MA (1) MA30296B1 (es)
MX (1) MX2008011340A (es)
NO (1) NO20084186L (es)
NZ (1) NZ571595A (es)
TW (1) TW200800897A (es)
WO (1) WO2007102127A2 (es)
ZA (1) ZA200808540B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005020314D1 (de) * 2004-08-25 2010-05-12 Actelion Pharmaceuticals Ltd Bicyclononen-derivate als renin-inhibitoren
GEP20115206B (en) * 2005-05-27 2011-04-26 Actelion Pharmaceuticals Ltd Novel piperidine carboxylic acid amide derivatives
EP1981847A1 (en) * 2006-02-02 2008-10-22 Actelion Pharmaceuticals Ltd. Secondary amines as renin inhibitors
US8129538B1 (en) 2007-03-28 2012-03-06 Takeda Pharmaceutical Company Limited Renin inhibitors
EP2162436A4 (en) 2007-05-24 2010-08-04 Merck Frosst Canada Ltd NEW CASE OF RENININHIBITORS
AU2008288648A1 (en) 2007-08-20 2009-02-26 Merck Frosst Canada Ltd. Renin inhibitors
EP2229363A4 (en) * 2007-12-04 2010-12-15 Merck Frosst Canada Ltd Renin Inhibitors
CA2722734C (en) 2008-05-05 2013-11-05 Merck Frosst Canada Ltd. 3,4-substituted piperidine derivatives as renin inhibitors
US20120190701A1 (en) * 2009-08-18 2012-07-26 Merck Sharp & Dohme Corp. Renin inhibitors
EP2832724A4 (en) * 2012-03-29 2015-09-23 Toray Industries NIPETIC ACID DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
WO2017082393A1 (ja) * 2015-11-12 2017-05-18 学校法人 聖マリアンナ医科大学 緑内障予防治療剤
JP2023545399A (ja) 2020-10-01 2023-10-30 バイエル アクチェンゲゼルシャフト ベンズアルデヒドオキシムおよびその製造方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380758A (en) * 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5175179A (en) * 1991-09-25 1992-12-29 Pfizer Inc. Method for treating hypertension
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
IT1295694B1 (it) * 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IT1292426B1 (it) * 1997-06-27 1999-02-08 Nicox Sa Sali nitrati di ace-inibitori
IL164767A0 (en) * 2002-04-29 2005-12-18 Actelion Pharmaceuticals Ltd 7-Aryl-3,9-diazabicyclo (3.3.1) non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertenision, cardiovascular or renal diseases
WO2004002957A1 (en) * 2002-06-27 2004-01-08 Actelion Pharmaceuticals Ltd Novel tetrahydropyridine derivatives as renin inhibitors
BRPI0409881A (pt) * 2003-04-29 2006-05-23 Actelion Pharmaceuticals Ltd compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
TW200513461A (en) * 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
JP2007508260A (ja) * 2003-10-09 2007-04-05 アクテリオン　ファマシューティカルズ　リミテッド 新規なテトラヒドロピリジン誘導体
US20070142363A1 (en) * 2003-10-13 2007-06-21 Actelion Pharmaceuticals Ltd Novel diazabicyclonene derivatives and use thereof
JP2007509099A (ja) * 2003-10-23 2007-04-12 アクテリオン　ファマシューティカルズ　リミテッド 新規ジアザビシクロノネンおよび新規極性側鎖を有するテトラヒドロピリジン誘導体
AU2004295092A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd. Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain
US20070111989A1 (en) * 2003-12-05 2007-05-17 Olivier Bezencon Novel diazabicyclononene derivatives and use
DE602005020314D1 (de) * 2004-08-25 2010-05-12 Actelion Pharmaceuticals Ltd Bicyclononen-derivate als renin-inhibitoren
US20080103152A1 (en) * 2004-12-08 2008-05-01 Actelion Pharmaceuticals Ltd Novel Diazabicyclononene Derivative
ATE514697T1 (de) * 2005-01-28 2011-07-15 Actelion Pharmaceuticals Ltd 7-ä4-ä2-(2,6-dichloro-4- methylphenoxy)ethoxyüphenylü-3,9- diazabicycloä3.3.1ünon-6-ene-6-carbonsäure- cyclopropyl-(2,3-dimethylbenzyl)amid als renin- hemmer für die behandlung von bluthochdruck
GEP20115206B (en) * 2005-05-27 2011-04-26 Actelion Pharmaceuticals Ltd Novel piperidine carboxylic acid amide derivatives
ZA200808419B (en) * 2006-03-03 2009-12-30 Actelion Pharmaceuticals Ltd Primary amines as renin inhibitors

Also Published As

Publication number Publication date
NO20084186L (no) 2008-10-07
NZ571595A (en) 2010-06-25
US20090062342A1 (en) 2009-03-05
CL2007000595A1 (es) 2008-01-04
BRPI0708567A2 (pt) 2011-05-31
TW200800897A (en) 2008-01-01
IL193885A0 (en) 2009-09-22
KR20090008211A (ko) 2009-01-21
MX2008011340A (es) 2008-09-12
JP2009529033A (ja) 2009-08-13
WO2007102127A3 (en) 2008-04-03
CA2642436A1 (en) 2007-09-13
MA30296B1 (fr) 2009-03-02
EP1994026A2 (en) 2008-11-26
ZA200808540B (en) 2009-12-30
CN101395149A (zh) 2009-03-25
AU2007224368A1 (en) 2007-09-13
WO2007102127A2 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
AR059886A1 (es) Derivados de amidas como inhibidores de renina
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
AR094452A1 (es) COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa
CO6300865A2 (es) Derivados polisustituidos de 2 aril-6-fenil-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica
CO5640152A2 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c
AR043508A1 (es) 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
AR082889A1 (es) Compuestos y composiciones para la inhibicion de nampt
AR056986A1 (es) Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
ES2678086T3 (es) Compuestos de diona cíclicos (alquil-fenil)-sustituidos activos como herbicidas y derivados de los mismos
AR049418A1 (es) Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
AR057408A1 (es) Agonistas del receptor de niacina composiciones que contienen tales compuestos y procedimientos para tratamiento
DOP2010000022A (es) Derivados de pirimidina 934
AR068658A1 (es) Derivados de tiazol
AR087470A1 (es) Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen
AR062499A1 (es) Derivados de n-fenil pirazol y piridil pirazoles, composiciones farmaceuticas que los contienen y usos como agentes antiagregantes plaquetarios y antitromboticos.
AR059284A1 (es) Derivados de aminas secundarias
AR066605A1 (es) Derivados de heteroarilamida pirimidona
AR069813A1 (es) Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento
UY32801A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR066524A1 (es) Azetidinas, composiciones farmaceuticas que las comprenden y uso como antagonistas de ep2
AR052055A1 (es) Derivados de biciclononeno

Legal Events

Date Code Title Description
FB Suspension of granting procedure